Related Experiment Video

Updated: May 8, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Sports doping: emerging designer and therapeutic β2-agonists

A G Fragkaki1, C Georgakopoulos, S Sterk

  • 1Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", Kifisias 37, 15123 Maroussi, Greece.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|August 20, 2013
PubMed

Keywords:
AAFBeta-agonistsCASCOMTCOPDCatechol-O-MethylTransferaseChronic Obstructive Pulmonary DiseaseCourt of Arbitration for SportDesigner drugsDetection methodsDoping controlELISAEUEnzyme-Linked Immunosorbent AssayEuropean UnionFDAFood and Drug AdministrationHP-TLCHRMSHigh Performance Thin Layer ChromatographyHigh Resolution Mass SpectrometryIACICSImmunoAffinity ChromatographyInhaled CorticosteroidLABALAMALC–MSLODLimit of DetectionLiquid Chromatography–Mass SpectrometryLong-Acting anti-Muscarinic AgentLong-Acting β(2)-AgonistMIPMRPLMinimum Required Performance LimitMolecular Imprinted PolymerMonoAmine OxidasePCIPositive Chemical IonizationRIARadioImmunoAssaySABASPESPRShort-Acting β(2)-AgonistSolid Phase ExtractionSurface Plasmon ResonanceTLCTOFThin Layer ChromatographyTime-of-FlightUPLCUVUltra Pressure (or Performance) Liquid ChromatographyUltravioletVeterinary drugsWADAWorld Anti-Doping Agencyadverse analytical findingΜΑΟ

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...